We report two cases of CsA-induced hyperkalemia in the setting of adequate renal function. Both patients had received a recent allogeneic bone marrow graft. Two adult leukemia patients underwent allogeneic bone marrow transplantation and received cyclosporine (CsA) as part of their immunosuppressive therapy. Despite adequate kidney function, both patients Case 1 developed hyperkalemia. Cyclosporine was the only pharmaceutical agent to which this electrolyte abnor-A 36-year-old male diagnosed with chronic myelogenous leukemia in 1991 underwent allogeneic bone marrow transmality could be attributed. Although the mechanism of the hyperkalemia is unclear, it seems to be related to plantation utilizing a five out of six phenotypically HLAmatched unrelated donor during 'accelerated' phase disease an aldosterone-resistant state. Cyclosporine-induced hyperkalemia is a relatively common occurrence; howstate in January 1994. The preparative regimen consisted of total body irradiation (120 cGy × 11 fractions with chest ever, there is only a single 'case report' addressing this phenomenon in bone marrow transplantation patients.
/day intravenous starting on day +5. CsA Despite its wide acceptance as an essential immunomodullevels were maintained between 200 and 400 ng/ml ator in bone marrow transplantation patients, CsA has mul-(monitored by gas-chromatography). The patient received tiple clinically significant side-effects. Most notable is that empiric antibiotics consisting of ceftazidime and ciproof its effect on renal function. 1, 2 Concern generally focuses floxacin as the absolute neutrophil count declined to less on its overall effect on glomerular filtration reflected by a than 500/mm 2 on day −7. Additional antimicrobial therapy decrease in creatinine clearance. Cyclosporine can also consisted of amphotericin-B which was started on day +12 cause hyperkalemia, presumably secondary to a direct due to persistent neutropenic fever. Other medication effect on distal renal tubular function, and on extra-renal included nifedipine, metaclopramide, acyclovir, sulcrafate, potassium handling. Animal studies have demonstrated an and inhaled pentamidine. The patient also received weekly inhibition of apical potassium secretory channels in the intravenous immunoglobulin infusions. principal cortical collecting tubule cells, caused by CsA.
3,4
Starting on day +22, the patient's potassium increased In the clinical setting, most reports dealing with CsA effect daily from 4.5 mg/dl to 5.9 mg/dl on day +25. Cyclosporine on potassium metabolism have involved solid organ translevels were between 256 and 325 ng/ml during the same plant patients. ium concentration gradient (TTKG) was calculated as 2.0, in a bone marrow transplant patient was felt to be due to secondary hypo-aldosteronism, as a hyporenin state was while the patient was maximally hyperkalemic. The plasma chloride and bicarbonate were 107 nmol/l and 22 nmol/l, persistently documented. 10 The TTKG is an indirect method of estimating the effect of aldosterone. A value below 5 in respectively. a hyperkalemic patient is suggestive of hypoaldosteronism. 9, 11 Our situation implies another possible mechanism of hyperkalemia, that of renal tubular defects secondary to Case 2 resistance to aldosterone. Despite 'adequate' aldosterone levels, the TTKG failed to reflect its influence on potassium A 25-year-old female diagnosed with acute promyelocytic leukemia in January 1993 underwent allogeneic bone marmetabolism. An effect of this insufficient aldosterone influence is a decrease in distal tubular flow rate resulting row transplantation in February 1994. The patient received a four out of six HLA-matched bone marrow from her sisin reduced potassium excretion. 12 This situation has been documented in settings outside bone marrow transplanter. Her preparative regimen consisted of total body irradiation (120 cGy × 11 fractions with a chest wall boost tation in which CsA was utilized. 4 Other mechanisms such as direct inhibition of tubular function by CsA has been on day −10 to day −8), etoposide (20 mg/kg i.v. on day −7), cytarabine (3 gm/m 2 intravenous on day −6 to day −4), proposed.
4
While the exact mechanism of potassium elevation while and cyclophosphamide (50 mg/kg intravenous on day −3 and day −2). The graft was depleted ex vivo of T cells using using CsA remains unresolved, there are measures which may aid in preventing such occurrences. One method would T10B9 along with rabbit complement. 8 Additional graftversus-host disease prophylaxis consisted of CsA be to avoid ACE-inhibitors and beta-blockers as hypotensive agents during CsA use. 3 The most simple and 5 mg/kg/day by continuous intravenous infusion starting on day −2 and methylprednisolone 30 mg/m 2 /day intraimportant therapeutic intervention is to decrease potassium administration. This manoeuver resolved both situations in venously starting on day +5. CsA levels were maintained between 200 and 400 ng/ml (by chromatography). The our report. If this fails to control the situation, one can utilize additional measures such as giving potassium 'wasting' patient received empiric antibiotics consisting of ceftazidime and ciprofloxacin i.v. on day −10 when the absolute pharmaceuticals and/or synthetic mineral corticoids. 13 Our results imply the latter action would be unsuccessful, unless neutrophil count was less than 500/mm 2 . Vancomycin was started on day 0. Amphotericin-B was added on day +2 one assumes there is a relative deficiency of aldosterone. Additionally, our results indicate that the development of due to persistent febrile neutropenia. Additional medication included acyclovir, ranitidine, intravenous immunoglobhyperkalemia may not necessarily be an acute event, as supported by the situation in case 1. Unfortunately, CsA is ulin, and inhalation pentamidine. The patient was also receiving parenteral nutrition containing 20 meq/l of potsuch a vital agent in bone marrow transplantation that discontinuing it is not an option. assium. Her serum potassium elevated from 4.2 mg/dl on day −2 to 5.8 mg/dl on day +1. Cyclosporine levels were
In conclusion, we provide additional evidence concerning CsA-associated hyperkalemia by addressing the issue between 190 and 386 ng/ml during the same time period. On day +1, a daily total of 30 meq of potassium was in bone marrow transplantation patients. Admittedly, as in most things post-transplant, it is difficult to attribute hyperremoved from both total parenteral nutrition and intravenous hydration fluids. The potassium returned to normal kalemia to a specific pharmaceutical agent such as CsA. To this end, we delineate two bone marrow transplant situlimits by day +4. During peak potassium levels, her serum creatinine was 0.6 mg/dl with a creatinine clearance of ations in which hyperkalemia was demonstrated in association with the fewest extraneous causes, outside the use 110 ml/min based on a 12-h urine collection. Her TTKG was calculated as 1.7 and her PM aldosterone level, in a of CsA. sitting position, on a random sodium diet, was 11 mg/dl. The plasma chloride and bicarbonate were 108 nmol/l and 21 nmol/l, respectively.
